Skip to main content
main-content

Oncology

Latest articles

27-06-2017 | Oncology | News | Article

ASCO 2017

Steady decline in serious comorbidities among pediatric cancer survivors

Research presented at the 2017 annual meeting of the American Society of Clinical Oncology shows childhood cancer survivors diagnosed in more recent years can expect to experience fewer serious chronic conditions than those diagnosed in earlier decades.

Source:

J Clin Oncol 2017; 35: LBA10500

26-06-2017 | Oncology | News | Article

ASCO 2017

Aldoxorubicin has activity in advanced soft tissue sarcoma

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

Source:

J Clin Oncol 2017; 35: 11000

23-06-2017 | Breast cancer | News | Article

Adjuvant capecitabine improves prognosis in high-risk breast cancer

Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

Source:

N Engl J Med 2017; 376: 2147–2159

23-06-2017 | Prostate cancer | News | Article

PAM50 classifier defines prostate cancer subtypes

Patients with prostate cancer can be classified into luminal- and basal-like subtypes using the well-known PAM50 algorithm, and the subtypes correlate with clinical outcome, researchers report.

Source:

JAMA Oncol 2017; Advance online publication

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

ASCO 2017

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Source:

J Clin Oncol 2017; 35: 7002

21-06-2017 | Non-small-cell lung cancer | News | Article

ASCO 2017

Dacomitinib improves EGFR-mutated NSCLC PFS over gefitinib, but at toxicity cost

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.

Source:

J Clin Oncol 2017; 35: LBA9007

image credits